Skip to main content

Table 2 Unadjusted hazard ratios for recurrence in relation to stromal ER and PR expression, allover and stratified by KRAS mutation status and sex, respectively

From: Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma

  All KRAS wild-type KRAS mutated  
n (events) HR (95% CI) n (events) HR (95% CI) n (events) HR (95% CI) Pinteraction
ER status
 All
  ER- 118 (84) 1.00 40 (23) 1.00 34 (29) 1.00 0.078
  ER+ 48 (36) 0.90 (0.61–1.33) 13 (10) 1.49 (0.71–3.15) 12 (8) 0.54 (0.24–1.19) 0.056a
  p   0.587   0.294   0.127  
 Women
  ER- 49 (32) 1.00 17 (9) 1.00 14 (10) 1.00 0.544
  ER+ 35 (24) 0.97 (0.57–1.65) 8 (5) 1.33 (0.44–4.00) 8 (5) 0.84 (0.28–2.53) 0.425a
  p   0.905   0.615   0.760  
 Men
  ER- 69 (52) 1.00 23 (14) 1.00 20 (19) 1.00 0.025
  ER+ 13 (12) 1.02 (0.54–1.92) 5 (5) 2.30 (0.78–6.78) 4 (3) 0.31 (0.08–1.11) 0.015a
  p   0.951   0.131   0.072  
PR status
 All
  PR- 111 (77) 1.00 38 (21) 1.00 29 (26) 1.00 0.005
  PR+ 49 (40) 1.25 (0.85–1.83) 12 (10) 2.07 (0.97–4.42) 17 (12) 0.50 (0.25–0.99) 0.008a
  p   0.252   0.061   0.048b  
 Women
  PR- 52 (33) 1.00 18 (9) 1.00 12 (10) 1.00 0.005
  PR+ 28 (22) 1.35 (0.79–2.33) 6 (5) 2.71 (0.89–8.26) 9 (5) 0.32 (0.11–0.97) 0.011a
  p   0.276   0.080   0.043b  
 Men
  PR- 59 (44) 1.00 20 (12) 1.00 17 (16) 1.00 0.337
  PR+ 21 (18) 1.20 (0.69–2.08) 6 (5) 1.64 (0.58–4.70) 8 (7) 0.84 (0.34–2.09) 0.249a
  p   0.510   0.353   0.715  
  1. aInteraction analysis including adjustment for morphological type (I-type/PB-type)
  2. bHazard ratio adjusted for morphological type 0.46 (0.23–0.93) in the entire cohort, and 0.32 (0.11–0.96) in women